Veru

Veru Net Change in Cash

The Net Change in Cash of Veru (VERU) as of Nov 17, 2026 is -9.12 M USD. In the previous year, Net Change in Cash was 15.29 M USD — a change of -159.66% (lower).

Net Change in Cash

-9.12 MUSD

YoY

-159.66%

Last updated:

Net Change in Cash of Veru is 2025 -9.12 M USD. Net Change in Cash of Veru was 2024 15.29 M USD. It decreases by -159.66% lower compared to the previous year.

The Veru Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
481,907.00 USD
Jan 1, 2019
2.54 M USD
Jan 1, 2020
7.29 M USD
Jan 1, 2021
108.77 M USD
Jan 1, 2022
-42.17 M USD
Jan 1, 2023
-70.57 M USD
Jan 1, 2024
15.29 M USD
Jan 1, 2025
-9.12 M USD
The Veru Net Change in Cash history
YEARNet Change in CashYoY
-9.12 MUSD-159.66%
15.29 MUSD-121.67%
-70.57 MUSD+67.34%
-42.17 MUSD-138.77%
108.77 MUSD+1,391.31%
7.29 MUSD+187.64%
2.54 MUSD+426.17%
481,907.00USD-46.01%
892,520.00USD-151.87%
-1.72 MUSD+1.79%
-1.69 MUSD-45.93%
-3.13 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veru Stock analysis

What does Veru do? Veru, Inc. generates revenue primarily through its Commercial segment, which focuses on FC2, a female condom product designed to prevent unintended pregnancy and sexually transmitted infections. The company's Research and Development segment develops multiple oncology and urology drug products, including VERU-111, VERU-100, and Zuclomiphene Citrate, targeting prostate cancer and breast cancer. These pipeline products are under clinical development and not yet commercialized. The Commercial segment's FC2 is sold to healthcare providers, distributors, and consumers seeking contraceptive and STI protection solutions. The Research and Development segment's drug candidates are not yet marketed, so revenue from this segment currently comes from partnerships or grants, though the business description does not specify such sources. Veru, Inc. operates in two segments: Commercial and Research and Development. The Commercial segment's FC2 product is the company's sole marketed product, while the Research and Development segment focuses on developing VERU-111, VERU-100, and Zuclomiphene Citrate for prostate cancer and breast cancer treatment. VERU-111 targets microtubules by crosslinking and disrupting alpha and beta tubulin subunits, and VERU-100 is a peptide formulation addressing limitations of androgen deprivation therapies for advanced prostate cancer. Zuclomiphene Citrate is part of the prostate cancer pipeline but lacks further detail in the description. The company's revenue streams are currently limited to FC2 sales in the Commercial segment, with no indication of revenue from the Research and Development segment's pipeline products. FC2 is marketed to healthcare providers, distributors, and end consumers for contraceptive and STI prevention purposes. The business description does not mention any other products, partnerships, or revenue sources beyond FC2 and the R&D pipeline. Veru is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veru stock

Net Change in Cash of Veru is -9.12 M USD in 2025.

Net Change in Cash of Veru changed from 15.29 M USD to -9.12 M USD, representing a -159.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Veru since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Veru historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Veru

All Key Metrics — Veru